Dr. Randal Chase is a respected leader with more than thirty years experience in the biotechnology sector.  Currently, he is President and CEO of ImmunoVaccine Technologies, providing expertise in strategy and tactics of drug development, financing and regulatory affairs.

He has served as President, CEO or a director of several world-class biotech companies.  His past positions include: President of Shire Biologics, President & CEO of North American Vaccine, President & CEO of Pasteur Merieux Connaught for Canada and Mexico (now Sanofi Adventis), President & CEO of Quadra Logic Technologies Inc. and Senior Vice President of Glaxo Canada Inc. Dr. Chase has overseen the complete development and commercialization of many products. As President & CEO, he has guided several companies through mergers, acquisitions and initial public offerings.  Additionally, he and his teams have raised over $25O million in equity and debt capital in both private and public markets. 

Dr. Chase has a Ph.D. in biochemistry from the University of British Columbia. He also attended the Executive Programme at the London Business School in the UK.  He has numerous contacts within the biotechology sector and is active as a board member with several companies and organizations, including: Chair of Medicago (TSX Venture), Bioject (NASDAQ), Acambis Inc. (FTSE and NASDAQ), Conjuchem (TSX), and BIOTECanada.

Marc Mansour, Ph.D.
Vice President R&D

Dr. Mansour received his doctorate from Dalhousie University in 2001.  His expertise lies in the field of molecular biology, cellular biology and immunology.  Dr Mansour has presented in numerous international conferences and has published in peer-reviewed journals in the areas of cell biology and cancer vaccines. Since he joined IVT, Dr. Mansour has advanced IVT’s research by tailoring the VacciMax® platform for a variety of contraceptive and infectious diseases vaccines. He worked extensively towards optimizing the VacciMax® platform for specific vaccine applications that are being developed in-house or in collaboration with commercial partners. He continues to lead the IVT science team in their efforts to optimize the platform and demonstrate manufacturability of VacciMax® -based vaccine products. 

Brian Lowe

Vice President

As an accomplished entrepreneur and businessman with over thirty years experience, Mr. Lowe brings invaluable expertise to ImmunoVaccine Technologies Inc (IVT).  Currently Mr. Lowe is Vice President of IVT and as a co-founder of the company is recognized for the incorporation and the initial funding of IVT and over $10 million in other startup funding.  Mr. Lowe’s past experience includes serving as the President/CEO/Founder of three environmental companies based in Dartmouth, Nova Scotia and successful negotiation of the sale of these companies to Laidlaw Environmental Services Ltd. in South Carolina.  Mr. Lowe is a co-founder and a director of the First Angel Network Association, Atlantic Canada’s Association for Private Investors and is a shareholder and Director of several operating companies throughout Atlantic Canada.  He is also a director of BioNova, Nova Scotia Life Sciences Association and a director of International Science and Technology Partnership Canada (ISTP Canada).

Ron Smith
Vice President Finance

Ronald E. Smith has over thirty years experience as a Chartered Accountant. As CFO of two major public companies, he has more than 16 years of experience serving Boards and Audit Committees directly. Mr. Smith is the Chairman of IVT’s Audit Committee. He has served on Boards and Audit Committees of three Canadian public companies, and numerous not-for-profit organizations over the past 20 years. He is currently serving on the Canada Pension Plan Investment Board, the crown corporation managing over $70 billion of Canada Pension Plan funds. Mr. Smith is the current Chair of Acadia University Board of Governors. He completed the ICD Corporate Governance College Directors Education Program and obtained ICD Certified Director designation in 2004. As a corporate director, Mr. Smith has been involved in four merger and acquisition transactions.